Press Releases

Mar 24, 2000	Summary Toggle Enzon, Inc. Raises an Additional $12.5 Million Through Exercise of Over-Allotment Option Enzon, Inc.
Mar 21, 2000	Summary Toggle Enzon, Inc. Prices Public Offering of 2 Million Shares of Common Stock at $44.50 per Share Enzon, Inc. Prices Public Offering of 2 Million Shares of Common Stock at $44.50 per Share PISCATAWAY, NJ--(BUSINESS WIRE)--March 21, 2000--Enzon, Inc., (NASDAQ: ENZN - news) announced that it has priced its public offering of 2 million newly issued shares of common stock at $44.50 per share.
Feb 23, 2000	Summary Toggle Enzon Announces Award in Arbitration with Yoshitomi for Recombinant HSA Enzon Announces Award in Arbitration with Yoshitomi for Recombinant HSA PISCATAWAY, NJ--(BUSINESS WIRE)--Feb. 23, 2000--Enzon, Inc. (NASDAQ: ENZN - news) announced today that arbitrators have ruled in a royalty dispute between Enzon and Yoshitomi Pharmaceutical Industries, Inc.
Feb 22, 2000	Summary Toggle Enzon Announces Schering-Plough's PEGINTRON Recommended for Approval for Treatment of Hepatitis C in European Union (EU) Enzon Announces Schering-Plough's PEGINTRON Recommended for Approval for Treatment of Hepatitis C in European Union (EU) PISCATAWAY, N.J.--(BUSINESS WIRE)--Feb. 22, 2000--Enzon, Inc.
Feb 22, 2000	Summary Toggle Enzon Announces Public Offering Enzon Announces Public Offering PISCATAWAY, N.J.--(BUSINESS WIRE)--Feb. 22, 2000--Enzon, Inc. (NASDAQ: ENZN - news) announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed offering of 2,000,000 shares of its common stock.
Feb 10, 2000	Summary Toggle Enzon Reports Schering-Plough's PEG-INTRON Accepted by the FDA for Review Enzon Reports Schering-Plough's PEG-INTRON Accepted by the FDA for Review PISCATAWAY, N.J.--(BUSINESS WIRE)--Feb. 10, 2000--Enzon, Inc.
Jan 5, 2000	Summary Toggle Enzon Announces Schering-Plough Submits U.S. Application for PEG-INTRON for the Treatment of Chronic Hepatitis C Enzon Announces Schering-Plough Submits U.S. Application for PEG-INTRON for the Treatment of Chronic Hepatitis C PISCATAWAY, N.J.--(BUSINESS WIRE)--Jan. 5, 2000--Enzon, Inc.